newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

  • Serina Therapeutics Inc. (NYSE: SER) announced that management will attend the BTIG Virtual Biotechnology Conference on July 28-29, 2026.
  • Virtual one-on-one investor meetings are scheduled for Wednesday, July 29, 2026, and can be requested through a BTIG representative.
  • The company's proprietary POZ Platform™ utilizes poly(2-oxazoline), a synthetic, water-soluble, low viscosity polymer to enable controlled drug loading & precise release rates for subcutaneous injections.
  • The platform aims to maintain stable blood levels for drugs with narrow therapeutic windows, reducing toxicity, side effects, & short half-lives associated with existing marketed drugs.
  • Serina intends to advance the POZ platform via out-licensing or partnerships, including a non-exclusive license agreement with Pfizer Inc. for use in lipid nanoparticle (LNP) drug delivery formulations.
  • SER-252 is an investigational apomorphine therapy designed to provide continuous dopaminergic stimulation (CDS) to reduce levodopa-related motor complications in Parkinson's disease without causing skin reactions.
  • The POZ Platform™ supports multiple modalities including small molecules, RNA-based therapeutics, & antibody-based drug conjugates (ADCs) for treating neurological diseases.
  • Serina Therapeutics is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology.